STL Index for: inflammation

Protected: What’s New in Pre-Aging Topical Modalities: The Clinical Efficacy of Acetyl Dipeptide-31 Amide

Santina Conte MD1, Monica K. Li MD FRCPC FAAD2 1Division of Dermatology, McGill University, Montreal, Quebec, Canada 2Department of Dermatology and Skin Science, University of British...

Real World Canadian Case Series: Use of Tildrakizumab for Moderate-to-Severe Psoriasis

Psoriasis vulgaris, or plaque psoriasis, is a chronic systemic inflammatory disease characterized by scaly, erythematous plaques. It is associated with comorbidities such as cardiovascular disease, metabolic syndrome, depression, and anxiety, signifi cantly aff ecting patients' quality of life. Tildrakizumab, an IL-23 inhibitor, is approved for treating adults with moderate-to-severe plaque psoriasis.

Lebrikizumab for Moderate-to-Severe Atopic Dermatitis

Lebrikizumab is a new IL-13 targeting monoclonal antibody approved for moderate-to-severe atopic dermatitis in patients 12+ years. Learn about clinical trial efficacy, safety data, dosing, and how it compares to other AD biologics like dupilumab and tralokinumab.

Nanodermatology

Nanodermatology uses nanoparticles (1-1000 nanometers) to enhance transdermal drug delivery for treating psoriasis, vitiligo, acne, and atopic dermatitis. Learn about nanocarriers, liposomes, and how nanotechnology improves topical medication penetration while reducing side effects.

Use of Nemolizumab in the Treatment of Prurigo Nodularis and Atopic Dermatitis

Nemolizumab, an IL-31 receptor antagonist, has demonstrated high efficacy and a favorable safety profile in phase 3 trials for prurigo nodularis and atopic dermatitis. Patients showed significant reductions in itch, improved skin lesions, and better quality of life over extended treatment periods.

A Novel Fixed Dose Triple Combination Therapy (IDP-126) for Moderate to Severe Acne

IDP-126 is a novel fixed-dose topical gel combining clindamycin, benzoyl peroxide, and adapalene for moderate to severe acne. Approved by the FDA and Health Canada, it showed superior efficacy over dual therapies in phase 2 and 3 trials, with strong safety and tolerability outcomes.

Roflumilast for the Treatment of Seborrheic Dermatitis: A Review

Explore the safety and efficacy of roflumilast 0.3% foam, a novel PDE-4 inhibitor, for treating seborrheic dermatitis. This review evaluates clinical trial outcomes, tolerability, and advantages compared to traditional therapies, highlighting its role as an effective, once-daily non-steroidal treatment option.

Targeting IL-23 in Psoriatic Arthritis: A Review of Guselkumab’s Efficacy and Utilization

Discover the role of IL-23 inhibition in psoriatic arthritis with a detailed review of guselkumab’s efficacy, safety, and practical use. This article summarizes key clinical trial findings, patient outcomes, and compares guselkumab to other biologic treatments, emphasizing its value as an alternative therapeutic option.

Pediatric Hidradenitis Suppurativa: An Overview

Explore a comprehensive overview of pediatric hidradenitis suppurativa (HS), a chronic inflammatory skin condition. This article delves into its epidemiology, pathogenesis, clinical features, associated comorbidities, and treatment challenges. Gain insights into the unique aspects of pediatric HS, including its impact on quality of life and the importance of early diagnosis and management.

A Review of the Role and Treatment of Biofilms in Skin Disorders

Learn about the role of biofilms in skin disorders like acne, atopic dermatitis, and chronic wounds. This article explores how biofilms contribute to disease pathogenesis, their resistance to antibiotics, and the latest conventional and innovative treatments aimed at targeting biofilm-associated skin conditions.

A Multimodal Approach to Acne-Induced Post-Inflammatory Hyperpigmentation: Trifarotene as a Long-Term Intervention

Discover how trifarotene, a fourth-generation retinoid, effectively treats acne and post-inflammatory hyperpigmentation (PIH). Learn about its benefits, clinical evidence, and role in managing acne sequelae.

Topical Roflumilast Cream for Plaque Psoriasis: Case Presentations to Primary Care

Explore two case studies of plaque psoriasis, treatment challenges, and novel therapeutic options, including topical roflumilast 0.3% cream. Learn how targeting PDE4 can improve psoriasis management, offering a non-steroidal, effective, and convenient solution for patients with different severities.

An Overview on the Management of Atrophic Acne Scars: The Role of Trifarotene as an Adjunct

Review of the effectiveness of trifarotene, a novel retinoid, in managing atrophic acne scars, highlighting its targeted action on retinoid acid receptor gamma (RAR-γ) and presenting recent clinical data supporting its use as a valuable adjunct treatment for acne scarring.

Adult Female Acne: Managing the Hormones

Explore the role of hormones in managing adult female acne with insights from Dr. Jennifer Lipson. Understand the pathophysiology, prevalence, and impact of hormonal therapies including oral contraceptives, spironolactone, and new topical treatments like clascoterone cream. Discover effective strategies for targeting hormones to treat this common and challenging condition.

A Review of the Use of Intravenous Immunoglobulin Therapy in Dermatology

This article reviews the use of intravenous immunoglobulin (IVIG) in dermatology, highlighting its role in treating autoimmune and inflammatory skin diseases. It discusses how IVIG reduces the need for steroids or immunosuppressants and its applications in conditions such as autoimmune bullous dermatoses, dermatomyositis, and Stevens-Johnson syndrome. The article also addresses dosing regimens, potential adverse effects, and the importance of ongoing research to further understand the efficacy and safety of IVIG in dermatologic treatments.

Long-Term Efficacy of Tildrakizumab in the Treatment of Psoriasis

A review of the long-term efficacy and safety of tildrakizumab, a monoclonal antibody targeting the IL-23/IL-17 pathway, in treating moderate-to-severe plaque psoriasis. Evidence from Phase 3 clinical trials and extension studies demonstrates that tildrakizumab is an effective and well-tolerated therapy, significantly improving skin clearance and maintaining a favorable safety profile over several years of use.

An Update on Current Clinical Management and Emerging Treatments in Hidradenitis Suppurativa

Explore current and emerging therapies for Hidradenitis Suppurativa (HS), a chronic, painful skin condition. This article reviews the challenges of HS treatment and introduces novel approaches including biologics like secukinumab and innovative therapies in clinical trials.

Overview of Dermatological Manifestations Associated with the COVID-19 Infection

Discover the diverse dermatological manifestations in COVID-19 patients, including chilblain-like lesions, maculopapular rashes, and necrosis, reflecting the virus's complex impacts beyond respiratory symptoms. This review highlights the need for further research into these skin conditions' pathogenesis and treatment.

Spesolimab, A Novel Interleukin-36 Inhibitor for Generalized Pustular Psoriasis Flares in Adult Patients

Explore the groundbreaking role of Spesolimab, a novel interleukin-36 inhibitor, in treating Generalized Pustular Psoriasis flares in adults. This article presents key findings from phase 1 and 2 clinical trials, emphasizing Spesolimab's effectiveness and safety.

1726 nm Lasers for the Treatment of Acne Vulgaris

Explore the efficacy of 1726 nm lasers, specifically AviClear and Accure systems, in treating moderate to severe acne vulgaris, offering a safe and effective alternative to systemic therapies.

Real-World Insights from Atopic Dermatitis Patients Treated with Abrocitinib

This real-world case series intends to illustrate a variety of moderate-to-severe AD patient cases to help guide discussions around abrocitinib and describe its treatment strategies used by experts in the field.

Risankizumab in Adults with Psoriatic Arthritis

Explore risankizumab for Psoriatic arthritis: Beyond ACR, it significantly improves enthesitis, dactylitis, and QoL scores like HAQ-DI. Promising in efficacy and safety, with full 208-week study results anticipated for a complete understanding.

Dupilumab for the Treatment of Prurigo Nodularis

Dupilumab: A groundbreaking FDA and Health Canada-approved treatment for Prurigo Nodularis (PN). This innovative therapy targets IL-4 and IL-13 signalling, effectively reducing inflammation, pruritus, and lesions. Its approval marks a paradigm shift in PN management, offering new hope for patients.

Topical Roflumilast for Plaque Psoriasis

Targeting PDE4 with the selective inhibitor roflumilast, specifically through topical cream at a concentration of 0.3%, has proven to be an effective and well-tolerated strategy for treating plaque psoriasis.

A Practical Guide to Advanced Topical Drug Delivery Systems in Dermatology

This guide will help you navigate the benefits of recent advancements in topical drug formulations and delivery systems. These innovations address limitations seen in older formulations, ensuring efficient and uniform delivery of active ingredients to target areas, improving patient acceptability, and enhancing treatment outcomes.

Casmo Prevention and Management of Four Common Cutaneous Toxicities Associated with Targeted Cancer Therapies: Papulopustular Eruption, Xerosis, Paronychia, and Hand-Foot Skin Reaction

Advances in cancer treatment have contributed to a reduction in mortality but survivors and healthcare providers should be aware of the potential adverse effects of these advanced treatments.

Managing Psoriasis with Topical Agents – Where Do We Stand?

Psoriasis vulgaris is a chronic, immune-mediated inflammatory skin disease affecting 2-4% of the Canadian population. While most psoriasis vulgaris cases are mild-to-moderate (>80%) and do not require systemic treatment, these cases can still be particularly challenging to treat as topical therapies present limitations, including efficacy and administration, leading to poor long-term treatment compliance and unsatisfactory treatment responses. The intent of this paper is to provide physicians with a clinically relevant review of the currently available and newly developed topical therapies...

The Evolving Story of JAK Inhibitors for Treating Alopecia Areata: A Review of Current Progress and Future Directions

Oral JAK inhibitors are now the first-line treatment for advanced alopecia areata, surpassing topical JAK inhibitors. Baricitinib's FDA approval in 2022 was a significant milestone. More JAK inhibitors are being studied, and additional medications may gain approval soon. JAK inhibitors show promise for alopecia areata with a generally good safety profile, but long-term data is lacking.

Utilization of Topical Ruxolitinib in Dermatology: A Review

Topical ruxolitinib shows promise in various dermatological conditions, including atopic dermatitis, vitiligo, psoriasis, and lichen planus, with a favorable safety profile compared to oral JAK inhibitors. However, its effectiveness in alopecia areata remains inconclusive.

Review of Dermato-Surgery Peri-Procedure Care Promoting Wound Healing

Peri-procedural measures in dermato-surgery depend on patient factors and procedure type. Standardized guidelines support healthcare providers in optimizing outcomes, preventing infection, and reducing recovery time. Research is needed to evaluate purpose-designed moisturizers for post-procedural application and improving patient outcomes.

Antibiotic Resistance in Dermatology Part 2: Combating Resistance

The proper and suitable application of antibiotics is crucial in maintaining their effectiveness amidst growing antibiotic resistance. Nevertheless, it is essential for prescribing practitioners to have a heightened understanding of resistance causes and strategies to counteract them.

Chlormethine Gel for the Treatment of Mycosis Fungoides (Cutaneous T-cell Lymphoma) in Canada

Chlormethine gel, a topical antineoplastic agent, has shown safety and efficacy in phase II trials and real-world data for treating adult Mycosis Fungoides patients. Despite potential skin-related side effects, chlormethine gel offers a convenient, skin-directed treatment for stage IA and IB MF-CTCL, addressing an unmet need in Canada.

Understanding Psoriasis: Insights from Les Journées Dermatologiques de Paris

Drs. Joël Claveau & Julien Ringuet, two Canadian dermatologists with prominent clinical and research practices, attended the Les Journées Dermatologiques de Paris conference in Nov-Dec 2022, with a focus on presentations and posters about psoriasis. This article reviews key insights they obtained at the meeting.

Tazarotene Lotion 0.045% for the Treatment of Acne (FP)

Topical retinoids are recommended as first-line therapy for most patients with acne. Tazarotene 0.045% lotion is a novel formulation that utilizes polymeric emulsion technology to improve tolerability and epidermal penetration.

Selective TYK2 Inhibition in the Treatment of Moderate to Severe Chronic Plaque Psoriasis

Moderate to severe chronic plaque psoriasis may be difficult to control using current therapies, which has led to development of a novel class of therapy, selective tyrosine kinase 2 (TYK2) inhibitors, to address this unmet need.

Toxic Epidermal Necrolysis: A Review of Past and Present Therapeutic Approaches

Toxic epidermal necrolysis (TEN) is an immune-mediated, severe cutaneous adverse drug reaction characterized by epidermal detachment affecting greater than 30% body surface area.

CaSMO Management of Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: A Practical Primer

The management of cirAEs starts with physician awareness and patient education on the occurrence of toxicities, preventive measures, and skincare using gentle cleansers, moisturizers, and sunscreen started before immunotherapy begins and ongoing thereafter as part of the lifestyle.

Tazarotene Lotion 0.045% for the Treatment of Acne

Tazarotene 0.045% lotion is a novel formulation which utilizes polymeric emulsion technology to improve tolerability and epidermal penetration. Despite the lower concentration of tazarotene in the lotion formulation, which likely also contributes to improved tolerability, tazarotene 0.045% lotion is at least as effective as tazarotene 0.1% cream.

Sarecycline: A Narrow-Spectrum Antibiotic

Sarecycline is a novel antibiotic that has shown significant promise in acne treatment due to its narrow-spectrum activity and weight-based dosing.

Topical Clascoterone for Acne Vulgaris

Clascoterone 1% cream represents a novel and promising therapeutic agent in the management of acne vulgaris for individuals ≥12 years of age. Notably, this topical agent was not observed to have significant systemic effects seen with systemic anti-androgenic agents.

POPULAR

Advertisement